Caribou Biosciences, a Berkeley, Calif.-based developer of technology-based solutions for cellular engineering and analysis, closed an $11m Series A financing round.
Backers included Fidelity Biosciences, Novartis, Mission Bay Capital, 5 Prime Ventures, an undisclosed strategic partner, and Dr. Jennifer Doudna, Investigator, Howard Hughes Medical Institute, Professor, U.C. Berkeley and co-founder of Caribou. In conjunction with the funding, Robert Weisskoff, Ph.D., a partner at Fidelity Biosciences, joined Caribou’s Board of Directors.
The company intends to use the funds to further accelerate deployment of its advanced genome editing platform.
Led by Rachel Haurwitz, Ph.D., Chief Executive Officer and co-founder, Caribou Biosciences is a developer of technology-based solutions for cellular engineering and analysis based on CRISPR-Cas9 biology. Its tools and technologies provide capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.
The company’s technologies are based on research into the biology of CRISPR-Cas systems carried out by the Doudna Lab at the University of California, Berkeley, and their collaborators.